Eli Lilly, a major pharmaceutical company, is teaming up with Superluminal Medicines to develop new treatments for obesity and metabolic diseases using artificial intelligence (AI). The deal, worth up to $1.3 billion, will allow Lilly to use Superluminal’s AI technology to discover and develop drugs that target specific proteins in the body linked to these conditions. In return, Superluminal will receive payments, including an upfront fee, equity investment, and future milestones based on the success of the drugs. This partnership is a big step for Superluminal, which started just two years ago with much smaller funding. For Lilly, this strengthens its portfolio of obesity and metabolic drugs, including Mounjaro and Zepbound, which together brought in over $8.5 billion in just three months. Superluminal’s CEO, Cony D’Cruz, expressed excitement about the collaboration, aiming to create new treatments for serious conditions like rare forms of obesity. The company is also working on an experimental drug targeting a protein that helps control appetite and weight. This isn’t Lilly’s first investment in this area—they’ve previously partnered with other companies for similar research. The goal is to bring safer and more effective treatments to patients struggling with these challenging health issues.